Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $105.2 million.

  • Innate Pharma's Liabilities and Shareholders Equity fell 3551.7% to $105.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $575.5 million, marking a year-over-year decrease of 2625.93%. This contributed to the annual value of $118.7 million for FY2024, which is 3703.82% down from last year.
  • Per Innate Pharma's latest filing, its Liabilities and Shareholders Equity stood at $105.2 million for Q2 2025, which was down 3551.7% from $118.7 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Liabilities and Shareholders Equity ranged from a high of $320.6 million in Q2 2021 and a low of $105.2 million during Q2 2025
  • In the last 5 years, Innate Pharma's Liabilities and Shareholders Equity had a median value of $212.1 million in 2022 and averaged $214.5 million.
  • As far as peak fluctuations go, Innate Pharma's Liabilities and Shareholders Equity crashed by 9990.37% in 2021, and later crashed by 666.35% in 2022.
  • Innate Pharma's Liabilities and Shareholders Equity (Quarter) stood at $306.0 million in 2021, then crashed by 30.7% to $212.1 million in 2022, then dropped by 11.12% to $188.5 million in 2023, then crashed by 37.04% to $118.7 million in 2024, then dropped by 11.36% to $105.2 million in 2025.
  • Its last three reported values are $105.2 million in Q2 2025, $118.7 million for Q4 2024, and $163.1 million during Q2 2024.